STENOCARE A/S

Innovative New ASTRUM Product Officially Approved for Sale in Norway: We are proud to announce the approval of our innovative product, Astrum 10-10, for sale in Norway. This milestone paves the way for more patients to access the benefits of medical cannabis treatment. Astrum 10-10 is expected to become available for patients within the next 30 days. Since 2019, Stenocare has been collaborating with partners to develop and test next-generation medical cannabis oil products, positioning itself as a frontrunner in prescription-based medical cannabis. Stenocare is now ready to introduce its patented product to Norwegian patients. Officially named “Astrum 10-10 Oil Stenocare,” the product contains 10 mg/ml THC and 10 mg/ml CBD in a 30 ml bottle. hInnovative Product: The Stenocare Astrum product leverages cutting-edge oil technology designed to enhance the bioavailability of cannabinoids in the patient’s bloodstream. This innovation addresses a well-known challenge in medication dosing by ensuring consistent absorption of active ingredients into the blood. With the Astrum product, Stenocare has successfully completed a pharmacokinetic (PK) study in dogs, documenting two critical parameters in the lymphatic system that can significantly improve bioavailability: • Parameter 1: Uptake in the Blood • Parameter 2: Time to Maximum Effectttps://https://lnkd.in/dvFDwjP3

Today, the Danish parliament formally agreed on permanent legalisation of medical cannabis. This is fantastic news for both Danish patients and Stenocare, as it ensures continued access to and the sale of medical cannabis in Denmark. Read the comments from Stenocare: https://lnkd.in/dXTGNaRA

Stenocare Announces Strategic Shift to Focus on Medical Cannabis Trading Stenocare A/S has unveiled its transformative STENOCARE 3.0 strategy, repositioning the Company as a leading Trading Company specialising in prescription-based medical cannabis. This strategic pivot includes exiting in-house production to concentrate solely on sales, marketing, and global distribution of high-quality, approved medical cannabis products. Sales-Driven Focus: - Launching ASTRUM, a newly approved patented medical cannabis oil product sourced from premier suppliers. - Expanding the sales of approved medical cannabis products across multiple target markets. Why This Shift? This decision aligns with the evolving medical cannabis industry, where specialised outsourcing has become the preferred model for achieving efficiency and strong ROI. By focusing on trading, Stenocare enhances its agility and build on its position in the growing global market for prescription-based medical cannabis. For more information, read the full press release: https://lnkd.in/ejFFg3YX

STENOCARE Welcomes Danish Health Minister’s Decision to Permanently Legalise Medical Cannabis for Patients The Danish Pilot Programme for medical cannabis is set to become a permanent legalisation for the treatment of Danish patients, according to the government. Today, the Danish Health Minister invited political parties to discuss the permanent legalisation of medical cannabis in Denmark. This is excellent news for Danish patients and Stenocare, as it secures future access to and sales of medical cannabis in Denmark. Stenocare sees this as a victory for Danish patients, Stenocare and the medical cannabis industry. The permanent legalisation will provide certainty for patients' continued treatment with medical cannabis, as it will no longer be limited to a temporary pilot programme. For the industry, the permanent legalisation will establish a clear framework for the future, offering clarity beyond December 2025 and justify investments in new products that deliver value to both doctors and patients. Stenocare CEO, Thomas Skovlund Schnegelsberg, is commenting: “Stenocare has been a leading supplier of medical cannabis products to the Danish Pilot Programme since 2018. The programme has provided valuable insights into the regulatory framework, patient treatment, the prescription process, and product subsidies. It is excellent news for patients and Stenocare that the government is now taking steps toward permanent legalisation. We were invited to provide input for the pilot evaluation report, which politicians will use in their work to define a permanent legalisation model for Denmark. We are confident that the future of medical cannabis treatment is in good hands.” https://lnkd.in/dAjD6nfE

New innovative Stenocare Astrum 10-10 oil product approved for sale in Germany   Stenocare and ADREXpharma are now ready to deliver a new and innovative medical cannabis oil product for German patients, that has the potential to revolutionize the market.   Stenocare and ADREXpharma have received approval to sell a new and innovative medical cannabis oil product in Germany, set to be available for patients in the fourth quarter of 2024.     The new product is a THC-CBD 10-10 oil in a 30 ml bottle which has the potential to address a large target group of patients in the German market.  Stenocare has since 2019 been investing with partners to develop and test next generation medical cannabis oil products, that can position Stenocare as a true leader within prescription-based medical cannabis. The new product-line is branded “Astrum”, and the company has worldwide exclusivity for this patented oil technology. The company is now ready to commercialize the product in the second market (Germany). The official German product name is “Astrum 10-10 Ext Stenocare”, with 10 mg/ml THC and 10 mg/ml CBD. Innovative product: The Stenocare Astrum product is based on an innovative oil technology, that has the potential to increase the cannabinoid’s bioavailability in the patient’s blood. Thereby, the new product is addressing a well-known challenge with dosing medicine and securing consistent uptake of the active ingredients in the blood. With the Astrum product, Stenocare has completed a pharmacokinetic (PK) study in dogs that documented two important parameters in the lymphatic system that can improve the bioavailability. For all the details, please read the press releaase: https://lnkd.in/dmMTnUqR

STENOCARE is expanding into Canada Stenocare is partnering with a team of industry experts in Canada to enter the market. Stenocare is one of the first European medical cannabis companies to enter Canada. In support of this growth strategy, the company has partnered with some of Canada’s leading medical cannabis innovators. Stenocare is planning to introduce its innovative “Astrum” oil product in the Canadian market. The Canadian medical market has seen very little investment focused on patient and consumer-facing innovation, and this offers Stenocare an opportunity to become a leader with a patient-first approach to medication delivery. Since 2019, Stenocare has been investing with partners to develop and test next-generation medical cannabis oil products, positioning Stenocare as a true leader within prescription-based medical cannabis. The new product line is branded “Astrum,” and the company has worldwide exclusivity for this patented oil technology. The company is shortly commercializing its first Astrum 10-10 oil in Australia. https://lnkd.in/eaEeWC64

STENOCARE has invested in research and development of this new product since 2019. We are excited that it will soon reach patients. #medicalcannabis #cannabisindustry

STENOCARE is Shortlisted for European Cannabis Company of the Year Stenocare is honored to be recognized as one of the leading European Cannabis Companies in the industry annual award. Stenocare has been an active participant in the European medical cannabis industry since it was founded in 2017. The company has entered six different countries with prescription-based medical cannabis products and has been an active participant in developing these markets. Now, Stenocare has been nominated and shortlisted in the annual industry awards as one of the best European Cannabis Companies of the Year. The European industry has hundreds of companies across the entire medical cannabis value chain, and a total of seven companies have been shortlisted for the prestigious award “European Cannabis Company of the Year.” The Business of Cannabis Awards are dedicated to honoring excellence in various facets of the cannabis sector, showcasing innovations, leadership, and growth within this dynamic industry. This year's event promises to be a remarkable gathering of industry leaders, innovators, and influencers. Comment from CEO, Thomas Skovlund Schnegelsberg: “We are both honoured and humbled by the recognition of being one of the best medical cannabis companies in Europe. We have a strategy of becoming a leading European brand within medical cannabis, and being shortlisted with a group of highly professional peers shows that we are on the right path toward that ambition.” The winner of “European Cannabis Company of the Year” will be announced during the annual industry conference “Cannabis Europa” in London on June 25. #medicalcannabis #cannabisindustry

An Update on Stenocare's Strong Product Pipeline Since 2019, Stenocare has invested in qualifying and developing the new and innovative ASTRUM Oil product. Through a pharmacokinetic study with dogs, it has documented improved bioavailability in the blood, enhanced uniformity of uptake, and reduced time for maximum uptake. Bringing true innovation to the market is a multi-year investment, and the Australian market is the first to benefit from this new product in Q3 2024. Stenocare continues its efforts in developing ASTRUM Oil for new markets. For full press release: https://lnkd.in/dtWYdzaQ

Product innovation: STENOCARE launch next generation medical cannabis oil product – six months ahead of schedule. The new Astrum brand is an innovative cannabis oil product featuring a patented oil technology that enhances the bioavailability of its active ingredients. This breakthrough allows for higher uptake in the blood, and reduced dosage requirements. For full press release: https://lnkd.in/dc8p2Hh3